Sufan Zheng

Associate

Overview

Sufan is an associate in the firm's Chicago office, focusing on intellectual property law, including patent litigation and prosecution. With a robust technical background and experience in multiple technical disciplines, she serves global clients across diverse industries, offering tailored legal solutions.

Sufan manages patent applications with meticulous drafting and responses to office actions before the U.S. Patent and Trademark Office, ensuring clients' innovations are well-protected. She supports partners and counsels in complex patent litigation, helping to develop strategies that protect and enforce clients' patent rights. Her expertise in material physics and materials engineering, enriched by research experience at Tsinghua University, enables her to tackle challenging technical issues effectively.

During law school, Sufan accumulated extensive practical experience in intellectual property. She interned at an IP law firm in New York, engaging with global clients on a large volume of AI-related patent applications. Additionally, as a student associate at the University of Wisconsin's Law and Entrepreneurship Clinic, she advised small businesses on IP strategy, honing her ability to deliver customized legal solutions.

Sufan’s broad experience with a wide range of inventions and global clients empowers her to leverage her unique skill set consistently, optimizing and safeguarding her clients’ innovations to ensure robust intellectual property portfolios.

Career & Education

    • Student Associate, Law and Entrepreneurship Clinic: University of Wisconsin Law School, 2023
    • Research Assistant: Tsinghua University, 2019–2022
    • Student Associate, Law and Entrepreneurship Clinic: University of Wisconsin Law School, 2023
    • Research Assistant: Tsinghua University, 2019–2022
    • University of Wisconsin – Madison, J.D., 2025
    • Tsinghua University, M.Eng., Materials Engineering, 2022
    • Fudan University, B.S., Material Physics, 2019
    • University of Wisconsin – Madison, J.D., 2025
    • Tsinghua University, M.Eng., Materials Engineering, 2022
    • Fudan University, B.S., Material Physics, 2019
    • Illinois
    • Wisconsin
    • Illinois
    • Wisconsin
    • Mandarin
    • Mandarin

Sufan's Insights

Client Alert | 3 min read | 05.21.26

Judge Jennifer Choe-Groves Takes Over Several DNJ Hatch-Waxman Cases

The U.S. Court of International Trade (CIT) is having a big year. While the U.S. Supreme Court’s affirmance of the CIT tariff ruling may be at the top of the headlines, the CIT is also making its mark on Hatch-Waxman pharmaceutical litigation. In late April 2026, the U.S. District Court for the District of New Jersey (DNJ) reassigned numerous Hatch-Waxman patent infringement cases involving 10 different drugs to Judge Jennifer Choe-Groves of the CIT, sitting by designation in the District of New Jersey. The cases currently assigned to Judge Choe-Groves relate to several different drug products, including LYNPARZA® (olaparib), RADICAVA ORS® (edaravone), NEXLETOL®/NEXLIZET® (bempedoic acid), ZEJULA® (niraparib), QULIPTA® (atogepant), UBRELVY® (ubrogepant), CREXONT® (carbidopa and levodopa), EVRYSDI® (risdiplam), SUFLAVE® (polyethylene glycol 3350, sodium sulfate, potassium chloride, magnesium sulfate, and sodium chloride for oral solution), and CAPLYTA® (lumateperone)....

Sufan's Insights

Client Alert | 3 min read | 05.21.26

Judge Jennifer Choe-Groves Takes Over Several DNJ Hatch-Waxman Cases

The U.S. Court of International Trade (CIT) is having a big year. While the U.S. Supreme Court’s affirmance of the CIT tariff ruling may be at the top of the headlines, the CIT is also making its mark on Hatch-Waxman pharmaceutical litigation. In late April 2026, the U.S. District Court for the District of New Jersey (DNJ) reassigned numerous Hatch-Waxman patent infringement cases involving 10 different drugs to Judge Jennifer Choe-Groves of the CIT, sitting by designation in the District of New Jersey. The cases currently assigned to Judge Choe-Groves relate to several different drug products, including LYNPARZA® (olaparib), RADICAVA ORS® (edaravone), NEXLETOL®/NEXLIZET® (bempedoic acid), ZEJULA® (niraparib), QULIPTA® (atogepant), UBRELVY® (ubrogepant), CREXONT® (carbidopa and levodopa), EVRYSDI® (risdiplam), SUFLAVE® (polyethylene glycol 3350, sodium sulfate, potassium chloride, magnesium sulfate, and sodium chloride for oral solution), and CAPLYTA® (lumateperone)....